Cargando…

529. Systematic Review and Meta-Analysis of Ivermectin Safety Profile in COVID-19 Trials

BACKGROUND: There is a continued and pressing need for safe and effective treatment of COVID-19. Significant survival benefits have been shown by dexamethasone, tocilizumab and sarilumab, however they are only recommended in hospitalised COVID-19 patients. Ivermectin is a well-established and readil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wentzel, Hannah, Wang, Junzheng, Dayanamby, Abbienaya, Pilkington, Victoria, Levi, Jacob, Hill, Andrew, Ellis, Leah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644070/ http://dx.doi.org/10.1093/ofid/ofab466.728

Ejemplares similares

Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
por: Hill, Andrew, et al.
Publicado: (2021)

Retraction to: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
por: Hill, Andrew, et al.
Publicado: (2022)

RETRACTED: Expression of Concern: “Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection”
por: Hill, Andrew, et al.
Publicado: (2021)

407. Minimum Manufacturing Costs, National Prices and Estimated Global Availability of New Repurposed Therapies for COVID-19
por: Wang, Junzheng, et al.
Publicado: (2021)

891. Minimum Manufacturing Costs and National Prices for Weight Loss Treatments, as Potential Mitigation for Anti-Retroviral Related Weight Gain in HIV
por: Levi, Jacob, et al.
Publicado: (2021)

Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud
por: Hill, Andrew, et al.
Publicado: (2022)

Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019
por: Wang, Junzheng, et al.
Publicado: (2021)

529. COVID-19 Antibody Responses in Solid Organ Transplant Recipients
por: Zervou, Fainareti, et al.
Publicado: (2020)

Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud
por: Hill, Andrew, et al.
Publicado: (2022)

Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19
por: Pepperrell, Toby, et al.
Publicado: (2020)

529. Overdiagnosis of Clostridioides difficile with a Multiplex PCR Panel
por: Arora, Vaneet, et al.
Publicado: (2018)

Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies during the Omicron (B.1.1.529) Surge: Data from the Patient-Reported Leukemia & Lymphoma Society National Registry
por: Reddy, Sneha T, et al.
Publicado: (2022)

Increased risk of psychosis to ivermectin treatment
por: Romero Calderon, A., et al.
Publicado: (2022)

529. Halting Multi-Modal Transmission of a Novel Carbapenemase-Producing Enterobacteriaceae Outbreak
por: Sickbert-Bennett, Emily, et al.
Publicado: (2019)

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study
por: Richard Hobbs, F D, et al.
Publicado: (2023)

PM529. Three clinical distinct groups according to medication adherence in rehospitalized patients with schizophrenia
por: Nam, Yulim, et al.
Publicado: (2016)

Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
por: Pepperrell, Toby, et al.
Publicado: (2022)

P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Mannelli, Francesco, et al.
Publicado: (2023)

529 Prevalence of Bronchitis and Revealing of the Risk Factors in the Children's Population
por: Adamia, Nino, et al.
Publicado: (2012)

Minimum costs to manufacture new treatments for COVID-19
por: Hill, Andrew, et al.
Publicado: (2020)

Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis
por: Nicolas, Patricia, et al.
Publicado: (2020)

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
por: Diaz, R, et al.
Publicado: (2009)

1946. Efficacy of Approved versus Unapproved Vaccines for SARS-CoV-2 Infection in Randomised Blinded Clinical Trials
por: Navarro, Andrea Perez, et al.
Publicado: (2022)

37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020)

631. Preliminary safety and pharmacokinetic profile of VIR-2482: a monoclonal antibody for the prevention of influenza A illness
por: Sager, Jennifer, et al.
Publicado: (2020)

145. the Efficacy and Safety of Low Dose Trimethoprim-sulfamethoxazole for the Treatment of Pneumocystis Pneumonia: A Systematic Review and Meta-analysis
por: Tritle, Brandon, et al.
Publicado: (2020)

PBPK modeling of ivermectin—Considerations for the purpose of developing alternative routes to optimize its safety profile
por: Rowland Yeo, Karen, et al.
Publicado: (2023)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

1210. K-mer Profiling Powered by Reference-assisted Assembly of NGS Data: A Highly Sensitive Protocol to Infer the Plasma Microbiome Using Cell-free DNA Sequence Data
por: Sinha, Rohita, et al.
Publicado: (2020)

Effectiveness and safety of ivermectin in the treatment of COVID-19: protocol for a systematic review and meta-analysis
por: Machado, Maria Letícia de Lima, et al.
Publicado: (2021)

493. Incidence and Characterization of Chronic Active COVID Among Patients Infected with the Novel Coronavirus (COVID-19) Receiving B-cell Depleting Therapies (BCDTs)
por: Kartes, Jacob, et al.
Publicado: (2021)

Trio sonatas, BWV 528, 529 and 530
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1993)

The truth about maximizing college 529 accounts
por: O'Shaughnessy, Lynn
Publicado: (2011)

Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers
por: Muñoz, Jose, et al.
Publicado: (2018)

Ivermectin – Old Drug, New Tricks?
por: Laing, Roz, et al.
Publicado: (2017)

1914. Characteristics of Hospital Onset SARS Cov-2 Infections Before and After the Emergence of The Highly Transmissible Variant B.1.1.529 In a Comprehensive Cancer Center
por: Dib, Rita Wilson, et al.
Publicado: (2022)

Distinct Evolutionary Profiles and Functions of microRNA156 and microRNA529 in Land Plants
por: Xie, Qi, et al.
Publicado: (2021)

529 Frequent Transmission of Clostridium Difficile by Asymptomatically Colonized Long-term Care Facility Residents during Hospital Admissions
por: Donskey, Curtis J., et al.
Publicado: (2014)

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
por: Pilkington, Victoria, et al.
Publicado: (2020)

245. The impact of patient safety report and sentinel events on the prescribing and practice habits of infectious disease physicians
por: Kollu, Vidya S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7i6ketp8v3guit4f2sqrj3b9hk